Apyx Medical (APYX) Registration Filing summary

Company overview and business model

• Operates in surgical aesthetics, offering innovative products like Helium Plasma Platform Technology, Renuvion®, AYON Body Contouring System™, and J-Plasma® for cosmetic and hospital surgical markets.

• AYON Body Contouring System™ integrates fat removal, contouring, and tissue contraction, recently FDA-cleared and launched commercially in September 2025.

• Leverages OEM agreements with other medical device manufacturers and maintains a global direct sales force and distributor network.

• Holds a robust intellectual property portfolio with 38 U.S. patents, 59 foreign patents, and multiple trademarks.

Market opportunity and competitive landscape

• The cosmetic surgery market is growing, driven by social media, societal beauty standards, and rising disposable income.

• GLP-1 drugs for weight loss have initially reduced surgeon revenue but are expected to increase demand for body contouring due to loose skin.

• Renuvion is the only FDA-approved device for treating skin laxity post-liposuction, expanding the addressable market.

• Liposuction remains the second most common aesthetic surgical procedure globally, with U.S. surgical procedures up 11.6% year-over-year.

Use of proceeds and capital allocation

• Net proceeds will be used for working capital, expanding sales and marketing, capital expenditures, facility expansion, acquisitions, and debt repayment.

• Management retains broad discretion over allocation based on operational needs and business growth.